You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 11, 2024

CLINICAL TRIALS PROFILE FOR HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Heparin Sodium 5,000 Units In Sodium Chloride 0.9%

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000468 ↗ Myocardial Infarction Triage and Intervention Project (MITI) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1988-04-01 To determine the practicality, benefit, and safety of paramedic administration of thrombolytic therapy for acute myocardial infarction. The feasibility of paramedics correctly identifying candidates for thrombolytic therapy following myocardial infarction was assessed in Phase I. In Phase II, pre-hospital thrombolytic therapy was compared with in-hospital thrombolytic therapy.
NCT00000468 ↗ Myocardial Infarction Triage and Intervention Project (MITI) Completed University of Washington Phase 3 1988-04-01 To determine the practicality, benefit, and safety of paramedic administration of thrombolytic therapy for acute myocardial infarction. The feasibility of paramedics correctly identifying candidates for thrombolytic therapy following myocardial infarction was assessed in Phase I. In Phase II, pre-hospital thrombolytic therapy was compared with in-hospital thrombolytic therapy.
NCT00182143 ↗ PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT) Completed Australian and New Zealand Intensive Care Society Clinical Trials Group Phase 3 2006-05-01 The purpose of this study is to evaluate the effect of Low Molecular Weight Heparin (LMWH) (Fragmin, dalteparin) versus Unfractionated Heparin (UFH) on the primary outcome of proximal leg Deep Vein Thrombosis (DVT) diagnosed by compression ultrasound, and the secondary outcomes of Pulmonary Embolism (PE), bleeding, Heparin-Induced Thrombocytopenia (HIT), and objectively confirmed venous thrombosis at any site.
NCT00182143 ↗ PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT) Completed Canadian Critical Care Trials Group Phase 3 2006-05-01 The purpose of this study is to evaluate the effect of Low Molecular Weight Heparin (LMWH) (Fragmin, dalteparin) versus Unfractionated Heparin (UFH) on the primary outcome of proximal leg Deep Vein Thrombosis (DVT) diagnosed by compression ultrasound, and the secondary outcomes of Pulmonary Embolism (PE), bleeding, Heparin-Induced Thrombocytopenia (HIT), and objectively confirmed venous thrombosis at any site.
NCT00182143 ↗ PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT) Completed Canadian Institutes of Health Research (CIHR) Phase 3 2006-05-01 The purpose of this study is to evaluate the effect of Low Molecular Weight Heparin (LMWH) (Fragmin, dalteparin) versus Unfractionated Heparin (UFH) on the primary outcome of proximal leg Deep Vein Thrombosis (DVT) diagnosed by compression ultrasound, and the secondary outcomes of Pulmonary Embolism (PE), bleeding, Heparin-Induced Thrombocytopenia (HIT), and objectively confirmed venous thrombosis at any site.
NCT00182143 ↗ PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT) Completed McMaster University Phase 3 2006-05-01 The purpose of this study is to evaluate the effect of Low Molecular Weight Heparin (LMWH) (Fragmin, dalteparin) versus Unfractionated Heparin (UFH) on the primary outcome of proximal leg Deep Vein Thrombosis (DVT) diagnosed by compression ultrasound, and the secondary outcomes of Pulmonary Embolism (PE), bleeding, Heparin-Induced Thrombocytopenia (HIT), and objectively confirmed venous thrombosis at any site.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Heparin Sodium 5,000 Units In Sodium Chloride 0.9%

Condition Name

Condition Name for Heparin Sodium 5,000 Units In Sodium Chloride 0.9%
Intervention Trials
Covid19 4
Myocardial Infarction 4
Healthy 4
Thrombosis 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Heparin Sodium 5,000 Units In Sodium Chloride 0.9%
Intervention Trials
Thrombosis 13
Venous Thrombosis 7
Acute Kidney Injury 6
COVID-19 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Heparin Sodium 5,000 Units In Sodium Chloride 0.9%

Trials by Country

Trials by Country for Heparin Sodium 5,000 Units In Sodium Chloride 0.9%
Location Trials
United States 44
China 16
Canada 14
Brazil 12
Germany 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Heparin Sodium 5,000 Units In Sodium Chloride 0.9%
Location Trials
California 7
New York 5
Texas 4
Ohio 3
Pennsylvania 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Heparin Sodium 5,000 Units In Sodium Chloride 0.9%

Clinical Trial Phase

Clinical Trial Phase for Heparin Sodium 5,000 Units In Sodium Chloride 0.9%
Clinical Trial Phase Trials
Phase 4 27
Phase 3 15
Phase 2/Phase 3 6
[disabled in preview] 27
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Heparin Sodium 5,000 Units In Sodium Chloride 0.9%
Clinical Trial Phase Trials
Completed 47
Unknown status 13
Withdrawn 10
[disabled in preview] 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Heparin Sodium 5,000 Units In Sodium Chloride 0.9%

Sponsor Name

Sponsor Name for Heparin Sodium 5,000 Units In Sodium Chloride 0.9%
Sponsor Trials
Ain Shams University 5
GlaxoSmithKline 4
Azidus Brasil 4
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Heparin Sodium 5,000 Units In Sodium Chloride 0.9%
Sponsor Trials
Other 143
Industry 35
NIH 5
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.